Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.006103805383556348 | N/A |
Market Cap | $11.24M | N/A |
Shares Outstanding | 1.84B | 114.61% |
Employees | 0 | N/A |
Shareholder Equity | 7.38M | -3.42% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 1078.34 | N/A |
P/B Ratio | 1.52 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.3125 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $10.42K | N/A |
Earnings | -$2.31M | N/A |
Gross Margin | 0.5999 | N/A |
Operating Margin | -236.41 | N/A |
Net income margin | -221.37 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $9.95M | N/A |
Total Debt | $4.32M | N/A |
Cash on Hand | $432.58K | N/A |
Debt to Equity | 0.6689 | 16.48% |
Cash to Debt | 0.1001 | 106.91% |
Current Ratio | 0.4039 | -9.61% |